Directed Evolution of AAV Serotype 5 for Increased Hepatocyte Transduction and Retained Low Humoral Seroreactivity

Most recombinant adeno-associated virus (AAV) capsids utilized in liver gene therapy have significant levels of pre-existing neutralizing antibodies in the human population. These neutralizing factors limit the patient pools eligible for receiving AAV-mediated therapies. AAV serotype 5 (AAV5) does n...

Descripción completa

Detalles Bibliográficos
Autores principales: Qian, Randolph, Xiao, Bin, Li, Juan, Xiao, Xiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773954/
https://www.ncbi.nlm.nih.gov/pubmed/33426144
http://dx.doi.org/10.1016/j.omtm.2020.10.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773954/
https://www.ncbi.nlm.nih.gov/pubmed/33426144
http://dx.doi.org/10.1016/j.omtm.2020.10.010

Ejemplares similares